Skip to main content
  • The PlexAPR test is a rapid test that measures the risk of any type of rejection of transplanted abdominal organs. This rejection may be due to T-cells which injure the transplanted organ directly, or B-cells, which produce antibodies against the transplanted organ.
  • Rejection is diagnosed with biopsies. Biopsies are performed when dysfunction of the transplanted organ is suspected from clinical symptoms and blood tests.
  • Biopsies are invasive, take some time to arrange and do not clearly distinguish between some types of viral infection which may co-exist with rejection.
  • Rapid non-invasive measurement of the risk of rejection within a few hours can permit the clinician to react sooner and improve management of transplanted organs experiencing organ dysfunction, while confirmatory biopsies are being arranged.
  • The principles of this test system are described here.
  • This test is under development. If you are interested in learning more, please subscribe to our updates.
  • To order tests or ask any questions, please reach us via email info@plexision.com or call us at +1 (855) 753-9474.

The PlexAPR test is a rapid test that measures the risk of any type of rejection of transplanted abdominal organs. This rejection may be due to T-cells which injure the transplanted organ directly, or B-cells, which produce antibodies against the transplanted organ.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact